Pemphigus vulgaris is a chronic blistering disease. Clinically it is characterized by painful intra-epidermal bullae and superficial vesicles involving both the skin and mucosal areas. The ...

Pemphigus is divided into two major subtypes: pemphigus vulgaris and pemphigus foliaceus. Oral corticosteroids are the primary treatment modality for pemphigus, while other therapeutic options ...

Pemphigus vulgaris is an autoimmune where the immune system produces antibodies against proteins in the skin and mucous membranes. Antibodies break bonds between cells leading to formation of skin ...

This is a schematic of how a "chimeric autoantibody receptor," or CAAR, that displays fragments of the autoantigen Dsg3 helps fight an autoimmune disease called pemphigus vulgaris, a condition in ...

The FDA has approved Genentech’s Rituxan (rituximab) for use in adults with moderate-to-severe pemphigus vulgaris (PV), making it the first treatment for the condition in more than 60 years.